LYPD3 and breast cancer: Gruet et al. [61] have shown that NE treatment increased invasive capacity in all breast cancer cell lines studied, while protein profiling revealed up-regulation of the pro-metastatic gene Ly6/PLAUR Domain-Containing Protein 3 (LYPD3) in NE-treated MDA-MB-468 breast cancer cells.